Lymphoma, Non-Hodgkin: all 2,043 studies
Page 19 of 21. Open to participants first (309), then studies with results posted, then the rest; newest registration first within each.
- Treatment for Subjects With Non-Hodgkin's LymphomaCompletedNCT00117897Phase 2
- A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's LymphomaCompletedNCT00117455Phase 2
- Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's LymphomaCompletedNCT00115193Phase 2
- ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic LeukemiaCompletedNCT00114348Phase 4
- Study of TPI 287 in Patients With Advanced MalignanciesCompletedNCT00113724Phase 1
- Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00110071Phase 1
- Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's LymphomaWithdrawnNCT00110006Not applicable
- Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00109824Phase 1
- Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic LeukemiaStatus unknownNCT00109356Phase 1/2
- A Safety Study of SGN-40 in Patients With Non-Hodgkin's LymphomaCompletedNCT00103779Phase 1
- 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic CancerTerminatedNCT00103272Phase 1
- Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or LymphomasCompletedNCT00101270Phase 1
- SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's LymphomaTerminatedNCT00101244Phase 1
- Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaTerminatedNCT00101205Phase 1
- Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)TerminatedNCT00100737Phase 2
- Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid TumorsTerminatedNCT00100347Phase 1
- Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell LymphomaCompletedNCT00099255Phase 2
- MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or LymphomasCompletedNCT00098891Phase 1
- Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00098566
- An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's LymphomaCompletedNCT00097565
- Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasTerminatedNCT00096005Phase 1
- Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)CompletedNCT00094848Phase 2
- Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular LymphomaStatus unknownNCT00091676Phase 3
- Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaStatus unknownNCT00090727Phase 1
- Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00090090Phase 2
- Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's LymphomaCompletedNCT00090038Phase 4
- 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomasCompletedNCT00089271Phase 1
- Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's LymphomaTerminatedNCT00089115Phase 3
- Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00087425Phase 2
- Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaCompletedNCT00086944Phase 1/2
- Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's LymphomaCompletedNCT00086034Phase 2
- Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell NeoplasmsCompletedNCT00082784Phase 1
- Music Imagery for Patients Receiving Chemotherapy for Leukemia or Non-Hodgkin's LymphomaCompletedNCT00082303Phase 1/2
- Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) PatientsStatus unknownNCT00081783Phase 2
- Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's LymphomaCompletedNCT00080886Phase 2
- S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's LymphomaTerminatedNCT00080847Phase 2
- Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell LymphomaCompletedNCT00079755Phase 2
- Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's LymphomaCompletedNCT00079261Phase 2
- Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell TransplantCompletedNCT00078858Phase 1/2
- A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's LymphomaStatus unknownNCT00078598Phase 3
- Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHLTerminatedNCT00077961Phase 1/2
- FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00077194Phase 2
- Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00077155Phase 1
- SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)CompletedNCT00076349Phase 2
- Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00073931Phase 2
- Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's LymphomaCompletedNCT00071955Phase 2
- Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First RelapseStatus unknownNCT00069966Phase 2
- Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's LymphomaCompletedNCT00069758Phase 2
- Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00068315Phase 1
- Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's LymphomaTerminatedNCT00068302Phase 1
- Meaning-Centered Psychotherapy in Advanced CancerCompletedNCT00067288Phase 2
- Pegfilgrastim PBPC Mobilization StudyCompletedNCT00066092Phase 2
- Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative DisorderCompletedNCT00064246Phase 1/2
- Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's LymphomaCompletedNCT00064116Phase 3
- Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 TositumomabCompletedNCT00062894Phase 1/2
- Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00062296Phase 2
- Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00062114Phase 2
- Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory LymphomaCompletedNCT00061672Phase 2
- Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgGCompletedNCT00061425Phase 1/2
- Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's LymphomaCompletedNCT00060684Phase 1
- Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's LymphomaTerminatedNCT00060671Phase 3
- Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's LymphomaTerminatedNCT00060385Phase 2/3
- Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1
- Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or LymphomaTerminatedNCT00060112Phase 1
- Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's LymphomaCompletedNCT00059904Phase 2
- Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin DiseaseTerminatedNCT00058773Phase 1
- Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGELCompletedNCT00058617Phase 1
- Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic LeukemiaTerminatedNCT00058461Phase 2
- Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell TransplantationCompletedNCT00058305Phase 2
- Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00058292Phase 1
- Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma PatientsTerminatedNCT00057447Phase 1/2
- Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's LymphomaTerminatedNCT00057343Phase 3
- Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's LymphomaCompletedNCT00055640Phase 2
- Study of 90Y-hLL2 to Treat Non-Hodgkin's LymphomaTerminatedNCT00054834Phase 1
- Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00054808Phase 2
- Bortezomib in Treating Patients With Advanced Cancer and Kidney DysfunctionCompletedNCT00054483Phase 1
- Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's LymphomaCompletedNCT00053768Phase 3
- Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaStatus unknownNCT00053105Phase 1
- Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's LymphomaCompletedNCT00052936Phase 3
- Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00052416Phase 1
- Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis FungoidesTerminatedNCT00052377Phase 1/2
- Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's LymphomaTerminatedNCT00051701Phase 1/2
- Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's LymphomaCompletedNCT00049439Phase 2
- Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's LymphomaCompletedNCT00048555Phase 1/2
- Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan TreatmentsCompletedNCT00045877Phase 2/3
- Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.CompletedNCT00045864Phase 2
- Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)CompletedNCT00044902Phase 2
- Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's LymphomaCompletedNCT00044551Phase 2
- Study of T900607-Sodium in Previously Treated Patients With Non-Hodgkin's Lymphoma.TerminatedNCT00043459Phase 2
- Epratuzumab in Treating Patients With Non-Hodgkin's LymphomaStatus unknownNCT00042913Phase 2
- Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's LymphomaStatus unknownNCT00041730Phase 2
- Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLLTerminatedNCT00041288Phase 2
- Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00040950Phase 1
- Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of ThrombocytopeniaCompletedNCT00039910Phase 3
- Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic CancerActive, not recruitingNCT00039676
- Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's LymphomaCompletedNCT00039351Phase 2
- BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's LymphomaStatus unknownNCT00039156Phase 2
- Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid MalignanciesTerminatedNCT00038883Not applicable
- Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure StatesTerminatedNCT00038779Not applicable
- A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's LymphomaCompletedNCT00038545Phase 2